- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Surrey and Irvine to investigate use of nanomaterials in stem cell therapies
University of Surrey researchers, Dr Alan Dalton and Dr Richard Sear, have received grants totalling £100k from the SETsquared Applied Collaborative Research Programme and the EPSRC to support collaborative work with the University of California, Irvine, researching the use of nanomaterials in stem cell growth.
The award will bring together Surrey's world-class expertise in materials and nano-technology with leading stem cell researchers at Irvine. It will develop new methods for studying and growing human embryonic stem cells, leading to new stem cell based therapies to treat human diseases. The research will tackle a key problem in growing embryonic stem cells, possible contamination from using 'feeder' cells and nutrients derived from animals. Surrey's work will lead to the development of wholly synthetic materials to create the structures on which stem cells are grown, reducing contamination of the new stem cells and increasing their safety.
The research has been made possible by the existence of the SETsquared collaborative programme between the four SETsquared partners (Universities of Surrey, Bath, Bristol and Southampton) and the University of California at San Diego and Irvine. The programme supports collaboration by providing pump priming funding to allow academics from the UK and US to meet and discuss detailed plans for initial experiments and proposal development. The programme also provides support in bid writing.
Further funding will be sought to develop the work further and commercialise it. Key polymer and nanotechnology companies have already expressed an interest in developing applications based on the results of this research.
Professor Peter Donovan, co-director of the Sue and Bill Gross Stem Cell Research Center at the University of California, Irvine comments that the work: "could facilitate methods for expanding stem cells in the scale required for both cell-based therapies and for high throughput drug screening. In addition, it may well turn out to be necessary to use such technology to develop certain specialised cells, such as bone, cartilage or muscle cell types which normally develop under stress."
The University of Surrey's Research & Enterprise Support department (RES) has been instrumental in setting up the UK/US programme and in supporting the development of this bid. RES will also provide ongoing support in IP protection and commercialisation.
About University of Surrey
The University of Surrey is one of the UK’s leading professional, scientific and technological universities with a world class research profile and a reputation for excellence in teaching and research. Ground-breaking research at the University is bringing direct benefit to all spheres of life – helping industry to maintain its competitive edge and creating improvements in the areas of health, medicine, space science, the environment, communications, defence and social policy. Programmes in science and technology have gained widespread recognition and it also boasts flourishing programmes in dance and music, social sciences, management and languages and law. In addition to the campus on 150 hectares just outside Guildford, Surrey, the University also owns and runs the Surrey Research Park, which provides facilities for 140 companies employing 2,700 staff.
The 2007 Guardian University League Table placed the University of Surrey 31st overall for its undergraduate programmes (out of 122 UK universities), which along with recognition from The Sunday Times for being ‘The University for Jobs', underlines the University’s growing reputation for providing high quality, relevant degrees.
The Sunday Times names Surrey as 'The University for Jobs' which underlines the University of Surrey's growing reputation for providing high quality, relevant degrees.
For more information, please click here
Press Office at the University of Surrey
Tel: 01483 689191
Tel: +44 (0) 1483 68 9314
Copyright © University of SurreyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016
New theory could lead to new generation of energy friendly optoelectronics: Researchers at Queen's University Belfast and ETH Zurich, Switzerland, have created a new theoretical framework which could help physicists and device engineers design better optoelectronics August 23rd, 2016
Researchers watch catalysts at work August 19th, 2016